• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    South Korea Clinical Trials Market

    ID: MRFR/HS/48503-HCR
    200 Pages
    Garvit Vyas
    September 2025

    South Korea Clinical Trials Market Research Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Therapeutic Area (Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology) and By End Use (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    South Korea Clinical Trials Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    South Korea Clinical Trials Market Summary

    The South Korea Clinical Trials market is projected to grow from 1.1 USD Billion in 2024 to 1.85 USD Billion by 2035.

    Key Market Trends & Highlights

    South Korea Clinical Trials Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 4.84 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 1.85 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 1.1 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of innovative technologies due to increasing demand for efficient clinical trial processes is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.1 (USD Billion)
    2035 Market Size 1.85 (USD Billion)
    CAGR (2025-2035) 4.84%

    Major Players

    MedPacto, Samsung Biologics, Korea Otsuka Pharmaceutical, CuroCell, Yuhan Corporation, Green Cross Holdings, Pharmicell, MediKorea, Celltrion, LG Chem, Hanmi Pharmaceutical, Daewoong Pharmaceutical, Korea United Pharmaceutical, Genexine, SK Biopharmaceuticals

    South Korea Clinical Trials Market Trends

    Remarkable trends are impacting the South Korea Clinical Trials Market. One of the key factors is the government’s investment to improve its healthcare facilities and associated policies, which speeds up the approval process for South Korean clinical trials. The Ministry of Food and Drug Safety in South Korea has developed a system that promotes safety, guaranteeing its innovation within medicine. This favorable atmosphere nurtures domestic and foreign pharmaceutical companies hoping to execute exercises in the region.

    There are plentiful possibilities in the field of new technologies, like artificial intelligence, and clinical trial design, including big data analytics. These technologies facilitate the recruitment and monitoring of clinical trial participants, thus enhancing the efficiency of South Korean clinical trials. Opportunities also arise from South Korea’s ever-increasing aging population as there is a growing need for clinical trials targeting age-related diseases.

    Recently, there has been a shift in focus towards participant specific demand tailoring strategies that improve recruitment. This trend towards targeted therapies is resulting in more defined clinical trial protocols directed toward specific patients. In addition to that, the adoption of remote clinical trials is improving accessibility for participants in the more rural regions of South Korea.

    In general, these trends indicate changes in the clinical trials market that appears to integrate new technology as well as the overall healthcare requirements of South Korea.

    South Korea Clinical Trials Market Drivers

    Market Segment Insights

    Get more detailed insights about South Korea Clinical Trials Market Research Report — Global Forecast till 2035

    Regional Insights

    Key Players and Competitive Insights

    The South Korea Clinical Trials Market operates within a dynamic environment characterized by a robust commitment to advancing medical research and innovative drug development. The market is witnessing significant growth, fueled by the increasing prevalence of chronic diseases, a rising aging population, and a government that supports the biopharmaceutical industry through favorable policies and funding. As a major hub for clinical research in Asia, South Korea boasts a wealth of resources, including advanced infrastructure, skilled professionals, and an increasing number of collaborative efforts between academic institutions and private entities.

    This competitive landscape is marked by the presence of both local and international players who contribute to the region's reputation for high-quality clinical trials, efficient regulatory processes, and rapid patient enrollment rates. The South Korea Clinical Trials Market serves as a critical component in the global clinical research framework, reflecting its advancements in technology and an emphasis on patient-centric studies.

    MedPacto has carved a niche for itself in the South Korea Clinical Trials Market with its specialized focus on innovative immunotherapy treatments, primarily for cancer. The company is well-positioned to leverage local expertise and networks to accelerate clinical trials, often resulting in quicker turnaround times compared to its competitors. By maintaining strategic collaborations with various research institutions and leveraging advanced technology platforms, MedPacto has developed a strong operational framework that facilitates efficient trial designs and execution.

    Its significant investment in R&D and focus on patient safety and regulatory compliance underscores MedPacto's dedication to producing high-quality, reliable data that can stand up to international scrutiny. Additionally, the company's commitment to transparency and ethical practices serves to bolster its reputation in a crowded market, making it a formidable player within South Korea's burgeoning clinical trials landscape.

    Samsung Biologics stands out in the South Korea Clinical Trials Market as a leader in biopharmaceutical manufacturing and development services. The company’s offerings span from early-stage research to large-scale commercial production, enabling it to provide a comprehensive suite of services to clients in the biotechnology sector. With state-of-the-art facilities that adhere to international standards, Samsung Biologics demonstrates considerable strengths in quality control and operational efficiency, which also contributes to its rapid growth and expansion in the market.

    The company strategically positions itself through mergers and acquisitions to enhance its capabilities and market reach continually. Samsung Biologics has established a strong presence in the local market, showing resilience and adaptability to evolving market conditions. By capitalizing on innovative technologies and forming alliances with other industry stakeholders, Samsung Biologics not only strengthens its product offerings but also plays a pivotal role in the overall growth and development of the clinical trials ecosystem in South Korea.

    Key Companies in the South Korea Clinical Trials Market market include

    Industry Developments

    The South Korea Clinical Trials Market has seen notable recent developments and current affairs. MedPacto has expanded its portfolio with promising new oncology candidates, and Samsung Biologics has strengthened its position by enhancing its contract manufacturing services, aligning with global demand for biopharmaceuticals. Korea Otsuka Pharmaceutical has been actively recruiting participants for innovative therapies focused on chronic diseases, reflecting increased investment in Research and Development.

    CuroCell recently announced advancements in cell therapy, contributing to the nation's growing reputation as a hub for clinical innovation. Yuhan Corporation and Green Cross Holdings have also been involved in noteworthy collaborations aimed at developing novel treatments for emerging health challenges. Furthermore, Pharmicell and MediKorea are advancing their respective gene and cell therapies, thereby attracting significant investment.

    In terms of mergers and acquisitions, in September 2023, Daewoong Pharmaceutical acquired a significant stake in a biotech firm to enhance its pipeline, while Genexine's strategic partnership with SK Biopharmaceuticals on joint clinical trials brings more resources to their collaborative efforts. The South Korea Clinical Trials Market is experiencing dynamic growth, driven by technological advancements and increasing global interest, positioning it as an essential player in the life sciences sector.

    Market Segmentation

    Clinical Trials Market Phase Outlook

    • Phase I
    • Phase II
    • Phase III
    • Phase IV

    Clinical Trials Market End Use Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Clinical Trials Market Study Design Outlook

    • Interventional
    • Observational
    • Expanded Access

    Clinical Trials Market Therapeutic Area Outlook

    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Endocrinology

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.01(USD Billion)
    MARKET SIZE 2024 1.1(USD Billion)
    MARKET SIZE 2035 1.85(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 4.84% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED MedPacto, Samsung Biologics, Korea Otsuka Pharmaceutical, CuroCell, Yuhan Corporation, Green Cross Holdings, Pharmicell, MediKorea, Celltrion, LG Chem, Hanmi Pharmaceutical, Daewoong Pharmaceutical, Korea United Pharmaceutical, Genexine, SK Biopharmaceuticals
    SEGMENTS COVERED Phase, Study Design, Therapeutic Area, End Use
    KEY MARKET OPPORTUNITIES Increased government funding initiatives, Rising patient enrollment rates, Advanced biopharmaceutical sector growth, Integration of digital health technologies, Expansion of CRO services and capabilities
    KEY MARKET DYNAMICS regulatory advancements, increasing patient recruitment, growing biopharmaceutical sector, collaboration with global firms, rising demand for innovative therapies
    COUNTRIES COVERED South Korea

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Leave a Comment

    FAQs

    What is the current market size of the South Korea Clinical Trials Market?

    The South Korea Clinical Trials Market is expected to be valued at 1.1 billion USD in 2024.

    What is the projected market size by 2035 for the South Korea Clinical Trials Market?

    By 2035, the South Korea Clinical Trials Market is projected to reach 1.85 billion USD.

    What is the expected CAGR for the South Korea Clinical Trials Market from 2025 to 2035?

    The expected CAGR for the South Korea Clinical Trials Market from 2025 to 2035 is 4.84%.

    Which phase of clinical trials has the highest market size in 2024 in South Korea?

    In 2024, Phase III of the clinical trials will have the highest market size, valued at 0.44 billion USD.

    What will be the market size for Phase I trials in South Korea by 2035?

    By 2035, the market size for Phase I trials in South Korea is expected to be 0.36 billion USD.

    Which major players are involved in the South Korea Clinical Trials Market?

    Some major players in the South Korea Clinical Trials Market include MedPacto, Samsung Biologics, and Yuhan Corporation.

    What are the projected market values for Phase II trials in 2024 and 2035?

    Phase II trials are projected to be valued at 0.24 billion USD in 2024 and 0.4 billion USD in 2035.

    What is the expected market size for Phase IV trials in South Korea by 2035?

    The expected market size for Phase IV trials in South Korea by 2035 is 0.34 billion USD.

    What are the anticipated growth drivers for the South Korea Clinical Trials Market?

    Key growth drivers for the South Korea Clinical Trials Market include increasing investments in drug development and a robust healthcare infrastructure.

    How is the South Korea Clinical Trials Market expected to evolve through the forecast period?

    The South Korea Clinical Trials Market is expected to evolve positively with significant growth anticipated due to advancing clinical research and technology enhancements.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. South Korea Clinical Trials Market, BY Phase (USD Billion)
    45. Phase I
    46. Phase II
    47. Phase III
    48. Phase IV
    49. South Korea Clinical Trials Market, BY Study Design (USD Billion)
    50. Interventional
    51. Observational
    52. Expanded Access
    53. South Korea Clinical Trials Market, BY Therapeutic Area (USD Billion)
    54. Oncology
    55. Cardiology
    56. Neurology
    57. Infectious Diseases
    58. Endocrinology
    59. South Korea Clinical Trials Market, BY End Use (USD Billion)
    60. Pharmaceutical Companies
    61. Biotechnology Companies
    62. Contract Research Organizations
    63. Competitive Landscape
    64. Overview
    65. Competitive Analysis
    66. Market share Analysis
    67. Major Growth Strategy in the Clinical Trials Market
    68. Competitive Benchmarking
    69. Leading Players in Terms of Number of Developments in the Clinical Trials Market
    70. Key developments and growth strategies
    71. New Product Launch/Service Deployment
    72. Merger & Acquisitions
    73. Joint Ventures
    74. Major Players Financial Matrix
    75. Sales and Operating Income
    76. Major Players R&D Expenditure. 2023
    77. Company Profiles
    78. MedPacto
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Samsung Biologics
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Korea Otsuka Pharmaceutical
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. CuroCell
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Yuhan Corporation
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Green Cross Holdings
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Pharmicell
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. MediKorea
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Celltrion
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. LG Chem
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Hanmi Pharmaceutical
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. Daewoong Pharmaceutical
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Korea United Pharmaceutical
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Genexine
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. SK Biopharmaceuticals
    163. Financial Overview
    164. Products Offered
    165. Key Developments
    166. SWOT Analysis
    167. Key Strategies
    168. References
    169. Related Reports
    170. South Korea Clinical Trials Market SIZE ESTIMATES & FORECAST, BY PHASE, 2019-2035 (USD Billions)
    171. South Korea Clinical Trials Market SIZE ESTIMATES & FORECAST, BY STUDY DESIGN, 2019-2035 (USD Billions)
    172. South Korea Clinical Trials Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2035 (USD Billions)
    173. South Korea Clinical Trials Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    174. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    175. ACQUISITION/PARTNERSHIP
    176. MARKET SYNOPSIS
    177. SOUTH KOREA CLINICAL TRIALS MARKET ANALYSIS BY PHASE
    178. SOUTH KOREA CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN
    179. SOUTH KOREA CLINICAL TRIALS MARKET ANALYSIS BY THERAPEUTIC AREA
    180. SOUTH KOREA CLINICAL TRIALS MARKET ANALYSIS BY END USE
    181. KEY BUYING CRITERIA OF CLINICAL TRIALS MARKET
    182. RESEARCH PROCESS OF MRFR
    183. DRO ANALYSIS OF CLINICAL TRIALS MARKET
    184. DRIVERS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    185. RESTRAINTS IMPACT ANALYSIS: CLINICAL TRIALS MARKET
    186. SUPPLY / VALUE CHAIN: CLINICAL TRIALS MARKET
    187. CLINICAL TRIALS MARKET, BY PHASE, 2025 (% SHARE)
    188. CLINICAL TRIALS MARKET, BY PHASE, 2019 TO 2035 (USD Billions)
    189. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2025 (% SHARE)
    190. CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2019 TO 2035 (USD Billions)
    191. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2025 (% SHARE)
    192. CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2019 TO 2035 (USD Billions)
    193. CLINICAL TRIALS MARKET, BY END USE, 2025 (% SHARE)
    194. CLINICAL TRIALS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    195. BENCHMARKING OF MAJOR COMPETITORS

    South Korea Clinical Trials Market Segmentation

     

     

     

    • Clinical Trials Market By Phase (USD Billion, 2019-2035)

      • Phase I
      • Phase II
      • Phase III
      • Phase IV

     

    • Clinical Trials Market By Study Design (USD Billion, 2019-2035)

      • Interventional
      • Observational
      • Expanded Access

     

    • Clinical Trials Market By Therapeutic Area (USD Billion, 2019-2035)

      • Oncology
      • Cardiology
      • Neurology
      • Infectious Diseases
      • Endocrinology

     

    • Clinical Trials Market By End Use (USD Billion, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials